Cabbage pharma
| kohlpharma | |
|---|---|
| legal form | GmbH |
| founding | 1979 |
| Seat | Merzig |
| management | Edwin Kohl, Jörg Geller, Gabriele Nilsson, Thilo Bauroth, Thilo Bauroth, Franz-Rudolf Weber |
| Number of employees | 853 (group-wide) |
| sales | 630 million euros (group-wide) |
| Branch | Pharma / pharmaceutical trade |
| Website | www.kohlpharma.com |
| As of December 31, 2018 | |
The Kohlpharma GmbH (proper spelling: kohlpharma ) is the largest German pharmaceutical importer (market share 2009: 29%), based in Merzig ( Saarland ). It is a major subsidiary of Kohl Medical AG, also based in Merzig ( proper spelling : KOHL MEDICAL ), in which other companies are also consolidated.
The company was founded in 1979 by Edwin Kohl. The purpose of the business was to import medical disposable items. From 1981 the focus was on the import of pharmaceuticals. In 1984 their nationwide sales started. The company has grown from a one-man operation to the largest German pharmaceutical importer. Ten years after the company was founded, sales in 1989 were 15 million German marks , and in 2001 sales exceeded the one billion German mark (514 million euros) for the first time. The turnover in 2011 amounted to 662 million euros minus 62 million manufacturer's compulsory discount (16% on turnover) in favor of the statutory health insurance .
The company today
kohlpharma has around 850 employees. In addition to the central company location in Merzig, there is a nationwide field service. The pharmaceuticals are sold both through pharmaceutical wholesalers and directly to every pharmacy nationwide within 24 hours . To this end, the largest and most modern pharmaceutical distribution center in Europe was built by 2001 .
The core business, the re-import of medicines from other EU countries and the subsequent re-labeling for the German internal market, is based on the different prices of the multinational pharmaceutical companies for the same product in the respective EU countries.
According to a study by the management consultancy Prognos - which was commissioned by the German Association of Drug Importers. V. (VAD), the CEO of which is the company's founder Edwin Kohl - this leads to savings of 264 million euros per year for the German health insurance companies.
In January 2013, the company took 218th place in the ranking of the 500 largest family businesses in the Wirtschaftsblatt magazine .
Lobbying
Kohlpharma is known from the media through its influence on the GSAV (law for more safety in the supply of pharmaceuticals) through personal telephone calls between the managing director Jörg Geller and the minister of economics Peter Altmaier. For example, the complete deletion of the import promotion clause initially requested in the GSAV was not enforced - contrary to the general consensus of 14 federal states.
Web links
Individual evidence
- ↑ www.kohlpharma.com , accessed April 4, 2014
- ↑ a b c d Annual financial statements of Kohl Medical AG as of December 31, 2018, published on bundesanzeiger.de
- ↑ www.impulse.de , accessed on April 4, 2011
- ↑ www.kohlpharma.com , accessed April 8, 2014
- ↑ www.kohlpharma.com , accessed April 8, 2014
- ↑ www.kohlpharma.com , accessed April 8, 2014
- ↑ About us. In: kohlpharma. Retrieved on October 14, 2019 (German).
- ↑ The largest family businesses in Germany. (PDF; 307 kB) In: Wirtschaftsblatt . Retrieved November 19, 2013 .
- ↑ parliamentwatch.de | Influence on the draft law: How Peter Altmaier campaigned for a company from his constituency. October 11, 2019, accessed October 14, 2019 .
- ↑ / bmwi-akte-gsav-ii. Retrieved October 14, 2019 .